GNI Ltd., an international biopharmaceutical company and leader in the field of integrated systems pharmacology, and Auckland UniServices Limited, New Zealand’s University of Auckland’s company for commercialization of technology developed at the University, announced today the establishment of a pioneering research collaboration to produce gene regulatory networks for melanoma and breast cancer. The research effort will also include studies to elucidate how these networks are affected as patients respond to various anti-cancer drugs.
